Rize Oncology (XCNQ:RIZE) YoY EBITDA Growth : 41.67% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Rize Oncology's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 41.67%.

Rize Oncology's EBITDA per Share for the three months ended in Dec. 2024 was C$-0.01.

Rize Oncology YoY EBITDA Growth Historical Data

The historical data trend for Rize Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology YoY EBITDA Growth Chart

Rize Oncology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

-2,200.00

-17.39

59.26

Rize Oncology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial												-9.09	-	-	-400.00	41.67

Rize Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Rize Oncology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-0.022	-	-0.022)	/	\| -0.022 \|
=	0.00 %

Rize Oncology's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(-0.007	-	-0.012)	/	\| -0.012 \|
=	41.67 %

Rize Oncology YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Rize Oncology's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Rize Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

RZONF:USA

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.rizeoncology.com

Rize Oncology Inc is is a biopharmaceutical company. The company is focused on the development of high-efficiency precision gene editing for human therapeutics applications. The company is also engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecules targeting soft tissue sarcoma and other cancers.

Executives

William James Garner	10% Security Holder, Director
Andre Pereira Fraga Figueiredo	Director

Rize Oncology Headlines

No Headlines